<unk>  is used as a treatment for major depressive disorder. Effectiveness appear to be similar to other antidepressants and in terms of effect size has been described as modest.<unk>  may be used when other treatments have failed. A 2017 Cochrane review on<unk>  determined that the place for it in the treatment of severe depression is unclear due to low-quality evidence and that more study is needed comparing<unk>  to selective serotonin reuptake inhibitors (SSRIs) which are typical first-line treatments.<unk>  is also used off-label for anxiety. A 2016 review found it was not useful in generalized anxiety disorder at 2.5, 5, and 10 mg doses (15 and 20 mg doses were not tested). A 2019 meta-analysis found that<unk>  didn't produce statistically significant results over the placebo in the symptoms, quality of life and remission rates of the generalized anxiety disorder, but it was well-tolerated. However, a 2018 meta-analysis supported use and efficacy of<unk>  for generalized anxiety disorder, though stated that more research was necessary to strengthen the evidence. A 2021 systematic review and meta-analysis concluded that there was uncertainty about the effectiveness of<unk>  for anxiety due to existing evidence being very low-quality. In a 2020 network meta-analysis of randomized controlled trials,<unk>  was associated with among the lowest remission rates for generalized anxiety disorder of the included medications (odds ratio = 1.30 for<unk> , range of odds ratios for other agents = 1.13–2.70). Effectiveness of<unk>  at 10, 15, and 20 mg/day versus placebo and duloxetine at 60 mg/day in the treatment of major depressive disorder in adults over 8 weeks (measured by improvement on the Montgomery–Åsberg Depression Rating Scale) in two randomized controlled trials. Changes in MADRS total score from baseline at week 8 were –10.8 to –12.8 for placebo, –13.0 to –15.6 for<unk> , and –16.9 for duloxetine. Dosage The recommended starting dosage of<unk>  is 10 mg/day. The dosage should then be increased as tolerated to 20 mg/day. For individuals who don't tolerate higher doses, 5 mg/day may be considered. The maximum recommended dose of<unk>  in known CYP2D6 poor metabolizers is 10 mg/day. Similarly, the dose should be reduced by half in those taking strong CYP2D6 inhibitors.<unk>  can be discontinued abruptly without tapering, but it is recommended that at doses of 15 to 20 mg/day it be tapered first to 10 mg/day one week prior to full discontinuation if possible. Available forms<unk>  is available in the form of 5, 10, 15 and 20 mg immediate-release, film-coated oral tablets.
Vortioxetine
Atomoxetine
Edivoxetine
Dapoxetine
Duloxetine
Fluparoxan
Nabilone
Fluoxetine